Thrombus Composition in Cerebral Infarctions: Study of Its Association With Plasma Biomarkers, Treatment Efficacy, Etiology and Prognosis.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Ischemic Stroke, Cerebral Veinous Thrombosis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Composition du Thrombus Dans Les Infarctus cérébraux : étude du Lien Avec Avec Des Biomarqueurs Plasmatiques, l'efficacité du Traitement, l'étiologie et le Pronostic.
Overview
This study focuses on thrombi collected during mechanical thrombectomy procedures, as well as on plasma biomarkers analyzed concomitantly. The primary objective of the study is to investigate associations and correlations between, on the one hand, the composition of thrombi retrieved during thrombectomy and, on the other hand, plasma biomarkers, treatment response, etiology, and prognosis of ischemic stroke and cerebral venous thrombosis. The secondary objectives of this study are to precisely characterize the biochemical composition of the thrombi (notably using techniques such as enzyme-linked immunosorbent assay \[ELISA\] following extraction of proteins contained within the thrombus), their histological structure (using standard histology with hematoxylin-eosin staining and immunohistochemistry), and their biological activity (in particular through in vitro assays assessing resistance to thrombolysis and the endothelial-adhesive or destructive properties of thrombi). Additional secondary objectives include testing new therapeutic methods for the lysis of thrombi collected by mechanical thrombectomy and establishing a link between thrombus transcriptomics and their confirmed etiology, particularly for thrombi initially described as having an embolic appearance and of undetermined etiology.
Primary outcome measures
- Diminution or increase of the NIHSS (National Institutes of Health Stroke Scale) score. The scale goes from 0 to 42, the higher, the more severe. [Time frame: In the 24 hours after the thrombectomy]
Eligibility criteria
Inclusion criteria
- Patients aged 18 years and older
- Presenting with cerebral infarction secondary to an arterial occlusion responsible for an ischemic stroke, or with cerebral venous thrombosis (CVT) having undergone a mechanical thrombectomy (MT) procedure
- Managed with mechanical thrombectomy
- Provision of free, informed, and explicit consent by the patient or their legal representative/next of kin (emergency inclusion procedure)
Exclusion criteria
- Patients under legal protection measures (e.g., guardianship or curatorship)
- Patients for whom the thrombectomy specimen cannot be retrieved or is not suitable for analysis (estimated at approximately 50% of patients undergoing MT)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Liebeskind DS, Sanossian N, Yong WH, Starkman S, Tsang MP, Moya AL, Zheng DD, Abolian AM, Kim D, Ali LK, Shah SH, Towfighi A, Ovbiagele B, Kidwell CS, Tateshima S, Jahan R, Duckwiler GR, Vinuela F, Salamon N, Villablanca JP, Vinters HV, Marder VJ, Saver JL. CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke. 2011 May;42(5):1237-43. doi: 10.1161/STROKEAHA.110.605576. Epu PMID 21393591
Identifiers
NCT: NCT07384520 · 2025-286